Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial
- Versteijne, E.
- Dam, J.L. van
- Suker, M.
- Janssen, Q.P.
- Groothuis, K.
- Akkermans-Vogelaar, J.M.
- Besselink, M.G.
- Bonsing, B.A.
- Buijsen, J.
- Busch, O.R.
- Creemers, G.J.M.
- Dam, R.M. van
- Eskens, F.A.L.M.
- Festen, S.
- Groot, J.W.B. de
- Koerkamp, B.G.
- Hingh, I.H. de
- Homs, M.Y.V.
- Hooft, J.E. van
- Kerver, E.D.
- Luelmo, S.A.C.
- Neelis, K.J.
- Nuyttens, J.
- Paardekooper, G.M.R.M.
- Patijn, G.A.
- Sangen, M.J.C. van der
- Vos-Geelen, J. de
- Wilmink, J.W.
- Zwinderman, A.H.
- Punt, C.J.
- Tienhoven, G. van
- Eijck, C.H.J. van
- Dutch Pancreatic Canc Grp
DOIAbstract
PURPOSE The benefit of neoadjuvant chemoradiotherapy in resectable and borderline resectable pancreatic cancer remains controversial. Initial results of the PREOPANC trial failed to demonstrate a statistically significant overall survival (OS) benefit. The long-term results are reported. METHODS In this multicenter, phase III trial, patients with resectable and borderline resectable pancreatic cancer were randomly assigned (1:1) to neoadjuvant chemoradiotherapy or upfront surgery in 16 Dutch centers. Neoadjuvant chemoradiotherapy consisted of three cycles of gemcitabine combined with 36 Gy radiotherapy in 15 fractions during the second cycle. After restaging, patients underwent surgery followed by four cycles of adjuvant gemcitabine. Patien...
Add to ORKG